Adaptimmune Therapeutics plc
ADAP
$0.2504
-$0.0735-22.69%
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -92.12% | -68.10% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -92.12% | -68.10% | |||
| Cost of Revenue | 14.19% | -15.19% | |||
| Gross Profit | -644.93% | -92.48% | |||
| SG&A Expenses | 34.25% | 11.50% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 21.87% | -6.64% | |||
| Operating Income | -339.47% | -121.37% | |||
| Income Before Tax | -332.04% | -123.96% | |||
| Income Tax Expenses | 103.73% | 57.98% | |||
| Earnings from Continuing Operations | -321.27% | -125.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -321.27% | -125.34% | |||
| EBIT | -339.47% | -121.37% | |||
| EBITDA | -419.97% | -116.60% | |||
| EPS Basic | -320.90% | -125.33% | |||
| Normalized Basic EPS | -278.29% | -123.93% | |||
| EPS Diluted | -348.48% | -128.71% | |||
| Normalized Diluted EPS | -278.29% | -124.33% | |||
| Average Basic Shares Outstanding | 0.06% | 0.07% | |||
| Average Diluted Shares Outstanding | 0.06% | -1.58% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
